Skip to content

Study · Observational study · 2023

4 results

Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries.

Cicione A, Nacchia A, Guercio A, Gravina C, Franco A, Grimaldi MC, Tema G, Lombardo R, Tubaro A, De Nunzio C

Prostate cancer and prostatic diseases14 Jan 2023Cited by 23 (Europe PMC)

PMID36641533 (opens in a new tab)DOI10.1038/s41391-022-00640-4 (opens in a new tab)PepBankPUB-36641533
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanObservational studySafety outcome

    In pharmacovigilance reports, cardiovascular events represented 214 of 4969 triptorelin adverse-event reports, reported as 5%.

    In plain wordsIn adverse-event databases, cardiovascular events represented 5% of triptorelin reports.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableReported cardiovascular adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Cardiovascular adverse-event reports
    214 reports
    triptorelin
    Proportion of adverse-event reports
    5%
    triptorelin

    Source sentences

    Summary
    and in 214/4969 (5%) for Triptorelin.
    2 context sentences
    Summary · context
    Aim of our study was to compare real-life data on AEs associated with GnRH agonists and GnRH antagonists based on Eudra-Vigilance (EV) and Food and Drug Administration (FDA) reported AEs.
    Summary · context
    EV and FDA databases were queried and the number of CV adverse events (AEs) for degarelix, buserelin, goserelin, leuprorelin, triptorelin until September 2021 were recorded.

Studies that did not test the peptide alone3

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studySafety outcome

    In pharmacovigilance data, pooled GnRH agonists including triptorelin had higher hypertension reporting risk than degarelix.

    In plain wordsIn adverse-event databases, pooled GnRH agonists including triptorelin had higher hypertension reporting risk than degarelix.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseHypertension reporting risk
    Study

    n: not reported in source

    Comparator
    Degarelix
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    PRR, degarelix versus GnRH agonists
    0.6 ratio
    degarelix versus GnRH agonists
    PRR interval
    0.37 to 0.98 ratio
    degarelix versus GnRH agonists

    Source sentences

    Summary
    Degarelix presented lower risk of hypertension (PRR 0.60 (95% CI 0.37-0.98), p = 0.04)
    3 context sentences
    Summary · context
    when compared to GnRH agonists.
    Summary · context
    Aim of our study was to compare real-life data on AEs associated with GnRH agonists and GnRH antagonists based on Eudra-Vigilance (EV) and Food and Drug Administration (FDA) reported AEs.
    Summary · context
    EV and FDA databases were queried and the number of CV adverse events (AEs) for degarelix, buserelin, goserelin, leuprorelin, triptorelin until September 2021 were recorded.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studySafety outcome

    In pharmacovigilance data, pooled GnRH agonists including triptorelin had higher myocardial infarction reporting risk than degarelix.

    In plain wordsIn adverse-event databases, pooled GnRH agonists including triptorelin had higher heart attack reporting risk than degarelix.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseMyocardial infarction reporting risk
    Study

    n: not reported in source

    Comparator
    Degarelix
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    PRR, degarelix versus GnRH agonists
    0.05 ratio
    degarelix versus GnRH agonists
    PRR interval
    0.01 to 0.39 ratio
    degarelix versus GnRH agonists

    Source sentences

    Summary
    of myocardial infarction (PRR 0.05 (95% CI 0.01-0.39), p < 0.01)
    3 context sentences
    Summary · context
    when compared to GnRH agonists.
    Summary · context
    Aim of our study was to compare real-life data on AEs associated with GnRH agonists and GnRH antagonists based on Eudra-Vigilance (EV) and Food and Drug Administration (FDA) reported AEs.
    Summary · context
    EV and FDA databases were queried and the number of CV adverse events (AEs) for degarelix, buserelin, goserelin, leuprorelin, triptorelin until September 2021 were recorded.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  3. 04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studySafety outcome

    In pharmacovigilance data, thrombosis reporting risk did not differ significantly between degarelix and pooled GnRH agonists including triptorelin.

    In plain wordsIn adverse-event databases, clot reporting risk did not differ significantly between degarelix and pooled GnRH agonists including triptorelin.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeThrombosis reporting risk
    Study

    n: not reported in source

    Comparator
    Degarelix
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    PRR, degarelix versus GnRH agonists
    0.14 ratio
    degarelix versus GnRH agonists
    PRR interval
    0.02 to 1.07 ratio
    degarelix versus GnRH agonists

    Source sentences

    Summary
    and thrombosis (PRR 0.14 (0.02-1.07), p = 0.06) when compared to GnRH agonists.
    2 context sentences
    Summary · context
    Aim of our study was to compare real-life data on AEs associated with GnRH agonists and GnRH antagonists based on Eudra-Vigilance (EV) and Food and Drug Administration (FDA) reported AEs.
    Summary · context
    EV and FDA databases were queried and the number of CV adverse events (AEs) for degarelix, buserelin, goserelin, leuprorelin, triptorelin until September 2021 were recorded.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 5Current

    27 Oct 2026, 16:37 UTC

    The same notice was added 3 times, first on 27 Oct 2026, 16:34 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.